$413 Million is the total value of ORACLE INVESTMENT MANAGEMENT INC's 21 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 29.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QDEL | Sell | QUIDEL CORP | $121,051,000 | +16.9% | 2,336,448 | -2.2% | 29.33% | +42.6% |
| AXK | Sell | ACCELERATE DIAGNOSTICS INC | $101,628,000 | -16.0% | 4,447,618 | -3.7% | 24.62% | +2.4% |
| TSRO | Sell | TESARO INC | $48,267,000 | -34.5% | 844,718 | -5.2% | 11.70% | -20.1% |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $19,552,000 | -12.4% | 9,537,661 | +12.8% | 4.74% | +6.8% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $15,581,000 | -38.4% | 5,176,479 | -17.9% | 3.78% | -24.8% |
| MZOR | Sell | MAZOR ROBOTICS LTDsponsored ads | $15,114,000 | -77.3% | 246,317 | -80.9% | 3.66% | -72.4% |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $14,937,000 | +116.5% | 1,330,070 | +28.8% | 3.62% | +164.0% |
| VRML | VERMILLION INC | $13,362,000 | -29.5% | 9,825,289 | 0.0% | 3.24% | -14.1% | |
| BIOL | BIOLASE INC | $12,532,000 | -4.8% | 30,866,262 | 0.0% | 3.04% | +16.1% | |
| OPK | Sell | OPKO HEALTH INC | $11,685,000 | -37.7% | 3,686,194 | -3.7% | 2.83% | -24.0% |
| AGEN | AGENUS INC | $7,288,000 | +44.5% | 1,547,392 | 0.0% | 1.77% | +76.2% | |
| EPZM | Buy | EPIZYME INC | $7,035,000 | +54.5% | 396,325 | +9.2% | 1.70% | +88.4% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $6,894,000 | +44.3% | 174,525 | +24.1% | 1.67% | +76.0% |
| CFRX | Buy | CONTRAFECT CORP | $5,147,000 | +75.7% | 3,167,013 | +9.2% | 1.25% | +114.3% |
| SLNO | SOLENO THERAPEUTICS INC | $4,330,000 | +0.7% | 2,388,060 | 0.0% | 1.05% | +22.8% | |
| ADRO | New | ADURO BIOTECH INC | $2,218,000 | – | 238,478 | +100.0% | 0.54% | – |
| QDEL | Buy | QUIDEL CORPcall | $2,151,000 | +195.1% | 198,300 | +89.2% | 0.52% | +259.3% |
| BIIB | BIOGEN INC | $1,744,000 | -14.0% | 6,368 | 0.0% | 0.42% | +5.0% | |
| BMY | New | BRISTOL MYERS SQUIBB COcall | $1,199,000 | – | 776,900 | +100.0% | 0.29% | – |
| AXK | Buy | ACCELERATE DIAGNOSTICS INCcall | $910,000 | -64.0% | 516,400 | +87.8% | 0.22% | -56.2% |
| EYES | SECOND SIGHT MED PRODS INC | $98,000 | +1.0% | 50,804 | 0.0% | 0.02% | +26.3% | |
| NXTM | Exit | NXSTAGE MEDICAL INCcall | $0 | – | -142,800 | -100.0% | -0.00% | – |
| TSRO | Exit | TESARO INCcall | $0 | – | -65,000 | -100.0% | -0.04% | – |
| ARAY | Exit | ACCURAY INC | $0 | – | -376,799 | -100.0% | -0.32% | – |
| ELGX | Exit | ENDOLOGIX INC | $0 | – | -362,727 | -100.0% | -0.39% | – |
| XON | Exit | INTREXON CORP | $0 | – | -195,000 | -100.0% | -0.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| OPKO HEALTH INC | 42 | Q3 2023 | 10.6% |
| PACIFIC BIOSCIENCES CALIF IN | 42 | Q3 2023 | 22.6% |
| BIOGEN INC | 42 | Q3 2023 | 0.6% |
| QUIDEL CORP | 36 | Q1 2022 | 52.5% |
| AMARIN CORP PLC | 31 | Q3 2021 | 23.1% |
| VERMILLION INC | 28 | Q1 2020 | 3.8% |
| AGENUS INC | 25 | Q3 2023 | 9.8% |
| TESARO INC | 23 | Q4 2018 | 27.8% |
| ACCELERATE DIAGNOSTICS INC | 23 | Q2 2023 | 23.0% |
| MAZOR ROBOTICS LTD | 20 | Q1 2018 | 18.0% |
View ORACLE INVESTMENT MANAGEMENT INC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View ORACLE INVESTMENT MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.